43 research outputs found

    Natural Resource Monitoring Progression of Forest Park’s Forested Natural Areas in St. Louis, Missouri

    Get PDF
    St. Louis City, MO had 121 acres managed as woodland or forested natural areas: 98 acres in Forest Park and 13 acres in O’Fallon Park. In Forest Park, standardized Missouri forest vegetation monitoring plots were started in 1993 to develop and guide habitat management such as thinning, species richness development, etc. In 2018 and 2019, a holistic Natural Resources Management Plan (NRMP) for Forest Park provided additional recommended metrics and monitoring, some of which have already begun implementation

    Restoration and Management of High-Use Urban Missouri Woodlands and Forests in St. Louis

    Get PDF
    St. Louis City’s urban woodland and forested natural areas were modified, degraded, and/or overly-mature habitats requiring management intervention for ecological health, species diversity, and public safety. To accomplish long-term success in Forest Park’s woodlands and forests, restorations and management strategies seeking to “treat the problem not the symptom” was implemented. The most important best management practices for Forest Park’s woodlands and forests included forest stand improvement, prescribed burns, invasive and non-native species management, creation of public stewards, and plant material supplementation

    Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes

    Get PDF
    publisher: Elsevier articletitle: Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes journaltitle: Cell articlelink: https://doi.org/10.1016/j.cell.2018.05.046 content_type: article copyright: © 2018 Elsevier Inc

    Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

    Get PDF
    Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≄ II, EF ≀35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation
    corecore